Article

An unknown genetic defect increases venous thrombosis risk, through interaction with protein C deficiency.

University of Utah, Department of Human Genetics, Salt Lake City, UT 84112-5330, USA.
The American Journal of Human Genetics (Impact Factor: 10.99). 09/1998; 63(2):569-76. DOI: 10.1086/301947
Source: PubMed

ABSTRACT We used two-locus segregation analysis to test whether an unknown genetic defect interacts with protein C deficiency to increase susceptibility to venous thromboembolic disease in a single large pedigree. Sixty-seven pedigree members carry a His107Pro mutation in the protein C gene, which reduces protein C levels to a mean of 46% of normal. Twenty-one carriers of the mutation and five other pedigree members had verified thromboembolic disease. We inferred the presence in this pedigree of a thrombosis-susceptibility gene interacting with protein C deficiency, by rejecting the hypothesis that the cases of thromboembolic disease resulted from protein C deficiency alone and by not rejecting Mendelian transmission of the interacting gene. When coinherited with protein C deficiency, the interacting gene conferred a probability of a thrombotic episode of approximately 79% for men and approximately 99% for women, before age 60 years.

0 Followers
 · 
66 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Menopausal hormone treatment (MHT) may limit progression of cardiovascular disease (CVD) but pose a thrombosis risk. To test targeted candidate gene variation for association with subclinical CVD defined by carotid artery intima-media thickness (CIMT) and coronary artery calcification (CAC), 610 women participating in the Kronos Early Estrogen Prevention Study (KEEPS), a clinical trial of MHT to prevent progression of CVD, were genotyped for 13,229 single nucleotide polymorphisms (SNPs) within 764 genes from anticoagulant, procoagulant, fibrinolytic or innate immunity pathways. Using linear regression, proportion of European ancestry correlated negatively, but age at enrollment and pulse pressure correlated positively with CIMT. Adjusting for these variables, two SNPs, one on chromosome 2 for MAP4K4 gene (rs2236935, β = 0.037, p-value = 2.36x10(-06)), and one on chromosome 5 for IL5 gene (rs739318, β = 0.051, p-value = 5.02x10(-05)) associated positively with CIMT; two SNPs on chromosome 17 for CCL5 (rs4796119, β = -0.043, p-value = 3.59x10(-05); rs2291299, β = -0.032, p-value = 5.59x10(-05)) correlated negatively with CIMT; only rs2236935 remained significant after correcting for multiple testing. Using logistic regression, adjusting for waist circumference, two SNPs (rs11465886, IRAK2, chromosome 3, OR = 3.91, p-value = 1.10x10(-04); and rs17751769, SERPINA1, chromosome 14, OR = 1.96, p-value = 2.42x10(-04)) associated positively with a CAC score of >0 AU; one SNP (rs630014, ABO, OR = 0.51, p-value = 2.51x10(-04)) associated negatively; none remained significant after correcting for multiple testing. Whether these SNPs associate with CIMT and CAC in women randomized to MHT remains to be determined.
    Physiological Genomics 11/2012; 45(2). DOI:10.1152/physiolgenomics.00114.2012 · 2.81 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Although there are a number of well-characterized genetic defects that lead to increased risk of thrombosis, little information is available on the relative importance of genetic factors in thrombosis risk in the general population. We performed a family-based study of the genetics of thrombosis in the Spanish population to assess the heritability of thrombosis and to identify the joint actions of genes on thrombosis risk and related quantitative hemostasis phenotypes. We examined 398 individuals in 21 extended pedigrees. Twelve pedigrees were ascertained through a proband with idiopathic thrombosis, and the remaining pedigrees were randomly ascertained. The heritability of thrombosis liability and the genetic correlations between thrombosis and each of the quantitative risk factors were estimated by means of a novel variance component method that used a multivariate threshold model. More than 60% of the variation in susceptibility to common thrombosis is attributable to genetic factors. Several quantitative risk factors exhibited significant genetic correlations with thrombosis, indicating that some of the genes that influence quantitative variation in these physiological correlates also influence the risk of thrombosis. Traits that exhibited significant genetic correlations with thrombosis included levels of several coagulation factors (factors VII, VIII, IX, XI, XII, and von Willebrand), tissue plasminogen activator, homocysteine, and the activated protein C ratio. This is the first study that quantifies the genetic component of susceptibility to common thrombosis. The high heritability of thrombosis risk and the significant genetic correlations between thrombosis and related risk factors suggest that the exploitation of correlated quantitative phenotypes will aid the search for susceptibility genes.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Protein C deficiency increases the risk of venous thromboembolic disease among members of KindredVermont 11, but fails to fully account for the inheritance pattern. A genome scan of the pedigree supported the presence of a prothrombotic gene on chromosome 11q23 (107-119Mb, nominal P < 0.0001), with weaker support on chromosomes 10p12 (11-25Mb, P < 0.0003) and 18p 11.2-q11 (12-24Mb, P < 0.0007).The 11q23 region contains the alpha(2) subunit (gene name PAFAH IB2) of platelet-activating factor acetylhydrolase 1b, a candidate prothrombotic gene. Re-sequencing of the PAFAH IB2 regulatory region in 137 pedigree members, including 25 thrombosis cases, revealed 12 variants; eight were present in only 0-2 affected individuals; the other four assorted into three haplotypes and included three variants predicted to destroy transcription factor-binding sites. More extensive re-sequencing of the PAFAH IB2 gene in I I affected and five unaffected pedigree members revealed an additional 13 variants that assorted into the same three haplotypes. We rejected as thrombosis risk factors each of the three presumed destructive variants as well as each of the three haplotypes. We also rejected (odds ratio=1.31 Cl: 0.91-1.88) one of the three variants in 469 cases and 472 controls from the Leiden Thrombophilia Study (LETS). Therefore, PAFAH IB2 is not the gene responsible for the linkage evidence on chromosome 11q23.
    Thrombosis and Haemostasis 09/2007; DOI:10.1160/TH07-02-0134 · 5.76 Impact Factor

Full-text (2 Sources)

Download
7 Downloads
Available from
Jun 3, 2014